ProCE Banner Activity

Why Long-Acting ART is the Latest Game Changer for HIV Treatment

Clinical Thought
Here are my thoughts on how the emergence of long-acting ART reflects the continued evolution of HIV treatment to better meet the broad needs of our patients and what ongoing research efforts may bring about for future long-acting ART options.

Released: November 30, 2021

Expiration: November 29, 2022

Share

Faculty

Jean-Michel Molina

Jean-Michel Molina, MD, PhD

Professor of Infectious Diseases
University of Paris Cité
Head of the Department of Infectious Diseases
Hospital Saint-Louis and lariboisière
Paris, France

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Gilead Sciences, Inc.

Faculty Disclosure

Primary Author

Jean-Michel Molina, MD, PhD

Professor of Infectious Diseases
University of Paris Cité
Head of the Department of Infectious Diseases
Hospital Saint-Louis and lariboisière
Paris, France

Jean-Michel Molina, MD, PhD, has disclosed that he has received consulting fees from Bristol-Myers Squibb, Gilead Sciences, Merck, and ViiV Healthcare and funds for research support from Gilead Sciences.